NYSE : EW

Edwards Lifesciences Corporation

$82.63 USD

-$1.19 (-1.42%)

Volume
9.26M
Average Volume
5.12M
Market Capitalization
$47.58B
P/E Ratio
47.49
Dividend Yield
0.00%
Price Target
$100.00
Year High
$96.29
Year Low
$72.30
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$4.42
Company Overview

NYSE

Bernard J. Zovighian

Medical - Devices

Healthcare

EW

16000

US

USD

https://www.edwards.com

949 250 2500

28176E108

0001099800

Liquidity Metrics

0.07

4.42

3.63

1.74

0.00

Sales & Valuation

$6.07B

7.31

4.61

43.67

1.89

Profitability

$1.83

$1.07B

15.43%

21.77%

9.71%

7.54%

P/E Metrics

47.49

-0.63

-0.63

Analyst Price Target & Rating

$100.00

$110.00

$85.00

Strong Sell

1/5

49 Analysts

-17.37%

Financial Health Scores

12.35

5/9

$4.82B

$13.32B

$2.99B

$1.42B

Key Metrics (TTM)

$45.83B

7.04

29.76

4.42

9.71%

10.58%

2.11%

2.29%

$26.51

293 days

Company Executives
Name Title
Daveen Chopra Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies
Dirksen J. Lehman Corporate Vice President of Public Affairs
Donald E. Bobo Jr. Corporate Vice President of Strategy & Corporate Development
Wayne T. Markowitz GM & Senior VP of Surgical Structural Heart
Gary I. Sorsher Senior Vice President of Quality & Regulatory Compliance
Annette Maria Bruls Corporate Vice President of EMEA, Canada, & Latin America
Todd Brinton FACC Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer
Andrew Dahl Principal Accounting Officer, Senior Vice President & Corporate Controller
Bernard J. Zovighian Chief Executive Officer & Director
Theodora Mistras Corporate Vice President & Chief Financial Officer
Snehashish Sarkar Senior VP and Chief Information & Digital Officer
Scott Ullem Corporate Vice President & Chief Financial Officer
Christine Z. McCauley Corporate Vice President of Human Resources
Joseph Nuzzolese Corporate Vice President of Global Operations & Quality
Mark D. Peterson Corporate Vice President & General Counsel
Poll Results

No votes yet today — be the first to share your view!

About Edwards Lifesciences Corporation (NYSE:EW) Stock

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, ... the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

2026-07-24 11:48:15

Edwards Lifesciences Corp. (NYSE:EW) stock rose Friday after the medical device maker reported second-quarter results that topped Wall Street estimates and raised the low end of its full-year revenue guidance.

Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises

2026-07-24 09:56:37

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.

Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Advancements

2026-07-24 00:00:00

Total Sales: $1.74 billion, a 12.5% increase year-over-year.Adjusted EPS: $0.78 for the quarter.TAVR Sales: $1.3 billion, a 10.5% increase over the prior year.

Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript

2026-07-23 20:30:32

Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript

Edwards Lifesciences Q2 Earnings Call Highlights

2026-07-23 19:06:41

Edwards Lifesciences NYSE: EW reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products.

Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

2026-07-23 19:00:55

The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Edwards Lifesciences beats quarterly estimates on strong demand for heart devices

2026-07-23 17:39:18

Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped ​by strong demand for its artificial heart ‌valves used in complex cardiac procedures, sending its shares up nearly 7% in extended trading.

Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth

2026-07-23 17:17:00

The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.

Frequently Asked Questions

What is the current Edwards Lifesciences Corporation (EW) stock price?

Edwards Lifesciences Corporation(NYSE:EW) stock price is $82.63 in the last trading session. During the trading session, EW stock reached the peak price of $96.29 while $72.3 was the lowest point it dropped to. The percentage change in EW stock occurred in the recent session was --1.42% while the dollar amount for the price change in EW stock was -$1.19.

EW's industry and sector of operation?

The NYSE listed EW is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of EW?

Daveen Chopra | Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies
Dirksen J. Lehman | Corporate Vice President of Public Affairs
Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development
Wayne T. Markowitz | GM & Senior VP of Surgical Structural Heart
Gary I. Sorsher | Senior Vice President of Quality & Regulatory Compliance

How many employees does EW have?

Number of EW employees currently stands at 16000. EW operates from One Edwards Way, Irvine, CA 92614, US.

Link for EW official website?

Official Website of EW is: https://www.edwards.com

How do I contact EW?

EW could be contacted at phone #949 250 2500 and can also be accessed through its website. EW operates from One Edwards Way, Irvine, CA 92614, US.

How many shares of EW are traded daily?

The average number of EW shares traded daily for last 3 months was 5.12M.

What is the market cap of EW currently?

The market value of EW currently stands at $47.58B with its latest stock price at $82.63